Thu | Jul 29, 2021

US officials extend expiration dates on J&J vaccine doses

Published:Thursday | June 10, 2021 | 12:16 PM
This Saturday, March 6, 2021, file photo shows vials of Johnson & Johnson COVID-19 vaccine at a pharmacy in Denver. On Thursday, June 10, 2021, Johnson & Johnson said that the US Food and Drug Administration extended the expiration date on millions of doses of its COVID-19 vaccine by an extra six weeks. (AP Photo/David Zalubowski, File)

WASHINGTON (AP) — Johnson & Johnson said Thursday that United States regulators extended the expiration date on millions of doses of its COVID-19 vaccine by an extra six weeks.

The company said a Food and Drug Administration review concluded the shots remain safe and effective up to 4 1/2 months.

The announcement comes after state officials warned that many unused doses in storage would expire before the end of the month.

Expiration dates for vaccines are determined based on data the manufacturer submits to regulators proving how long the shots stay at the right strength.

FDA originally authorised J&J's vaccine for use for up to three months after manufacture when stored at normal refrigeration levels.

But J&J said the FDA extended the period to 4 1/2 months, based on data from ongoing studies assessing the vaccine's stability.

The FDA has been reviewing expiration dates on the three authorised vaccines as companies have continued to test samples of batches in the months since the shots first rolled out.

The extension will help maintain vaccine supplies even as the rate of new injections continues to slip.

The country averaged about 800,000 new injections per day last week.

That's down from a high of nearly two million per day two months ago.

Government officials have turned to a growing number of incentives to encourage shots - from paid time off to $1 million lottery prizes.

As vaccinations have slowed it's become clear the US is unlikely to meet President Joe Biden's goal target to have 70% of American adults partially vaccinated by July 4.

Roughly, 64% of Americans older than 18 have had at least one dose, according to the Centers for Disease Control and Prevention.

J&J's vaccine was highly anticipated because of its one-and-done formulation and easy-to-ship refrigeration requirements.

The shot was expected to play a key role in vaccination campaigns in rural areas and low-income countries with limited health care infrastructure.

But rival drugmakers Pfizer and Moderna have already supplied more than enough doses to meet US demand, with more than 129 million Americans fully vaccinated with the companies' two-dose shots.

By comparison, just 11 million Americans have been vaccinated with the J&J shot.

The US is set to announce plans to donate 500 million Pfizer vaccine doses for global use over the next year, on top of 80 million doses already pledged by the end of the month.

Uptake of J&J's vaccine in the US has also been hurt by contamination problems at a Baltimore factory that helps manufacture the shots.

The facility was shuttered after an FDA inspection uncovered multiple problems in April and none of the vaccines made there have been distributed.

Follow The Gleaner on Twitter and Instagram @JamaicaGleaner and on Facebook @GleanerJamaica. Send us a message on WhatsApp at 1-876-499-0169 or email us at onlinefeedback@gleanerjm.com or editors@gleanerjm.com.